Tumor Microenvironment in Ovarian Cancer Peritoneal Metastasis

Overview

Journal Cancer Cell Int

Publisher Biomed Central

Date 2023 Jan 26

PMID 36698173

Authors

Shuangshuang Mei

Xing Chen

Kai Wang

Yuxin Chen

Affiliations

Soon will be listed here.

Abstract

Ovarian cancer (OC) is one of the most common gynecological malignancies with high morbidity and mortality. The peritoneum is one of the most common metastatic sites in ovarian cancer, involving large amounts of ascites. However, its mechanism is unclear. The peritoneal microenvironment composed of peritoneal effusion and peritoneum creates favorable conditions for ovarian cancer progression and metastasis. Here, we reviewed the peritoneal metastasis patterns and molecular mechanisms of ovarian cancer, as well as major components of the peritoneal microenvironment, peritoneal effusion, and immune microenvironment, and investigated the relationship between the peritoneal microenvironment and ovarian cancer metastasis.

Citing Articles

Advanced Therapeutic Approaches for Metastatic Ovarian Cancer.

Choe S, Jeon M, Yoon H Cancers (Basel). 2025; 17(5).

PMID: 40075635 PMC: 11898553. DOI: 10.3390/cancers17050788.

Repurposing the anti-parasitic agent pentamidine for cancer therapy; a novel approach with promising anti-tumor properties.

Rastegar-Pouyani N, Farzin M, Zafari J, Haji Abdolvahab M, Hassani S J Transl Med. 2025; 23(1):258.

PMID: 40033361 PMC: 11877826. DOI: 10.1186/s12967-025-06293-w.

Paired primary-metastasis patient-derived organoids and mouse models identify phenotypic evolution and druggable dependencies of peritoneal metastasis from appendiceal cancer.

Mahmoud A, Choi P, Sukhwa C, Pintar J, Walch H, Zhao N bioRxiv. 2025; .

PMID: 40027618 PMC: 11870485. DOI: 10.1101/2025.02.17.638725.

The Role of Douglasectomy Instead of Random Biopsies in the Surgical Treatment of Presumed FIGO Stage I Ovarian Cancer.

Tsolakidis D, Zouzoulas D, Tzitzis P, Sofianou I, Theodoulidis V, Chatzistamatiou K Cancers (Basel). 2025; 17(3).

PMID: 39941788 PMC: 11816186. DOI: 10.3390/cancers17030419.

Jackson G, Adamson D Cells. 2025; 14(3).

PMID: 39936963 PMC: 11816616. DOI: 10.3390/cells14030171.

References

Hao Q, Li J, Zhang Q, Xu F, Xie B, Lu H . Single-cell transcriptomes reveal heterogeneity of high-grade serous ovarian carcinoma. Clin Transl Med. 2021; 11(8):e500. PMC: 8335963. DOI: 10.1002/ctm2.500. View

Scotton C, Wilson J, Scott K, Stamp G, Wilbanks G, Fricker S . Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res. 2002; 62(20):5930-8. View

Kenny H, Kaur S, Coussens L, Lengyel E . The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest. 2008; 118(4):1367-79. PMC: 2267016. DOI: 10.1172/JCI33775. View

Thomakos N, Diakosavvas M, Machairiotis N, Fasoulakis Z, Zarogoulidis P, Rodolakis A . Rare Distant Metastatic Disease of Ovarian and Peritoneal Carcinomatosis: A Review of the Literature. Cancers (Basel). 2019; 11(8). PMC: 6721345. DOI: 10.3390/cancers11081044. View

Albrengues J, Bertero T, Grasset E, Bonan S, Maiel M, Bourget I . Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts. Nat Commun. 2015; 6:10204. PMC: 4682161. DOI: 10.1038/ncomms10204. View

Carduner L, Leroy-Dudal J, Picot C, Gallet O, Carreiras F, Kellouche S . Ascites-induced shift along epithelial-mesenchymal spectrum in ovarian cancer cells: enhancement of their invasive behavior partly dependant on αv integrins. Clin Exp Metastasis. 2014; 31(6):675-88. DOI: 10.1007/s10585-014-9658-1. View

de Almeida P, Mak J, Hernandez G, Jesudason R, Herault A, Javinal V . Anti-VEGF Treatment Enhances CD8 T-cell Antitumor Activity by Amplifying Hypoxia. Cancer Immunol Res. 2020; 8(6):806-818. DOI: 10.1158/2326-6066.CIR-19-0360. View

Baci D, Bosi A, Gallazzi M, Rizzi M, Noonan D, Poggi A . The Ovarian Cancer Tumor Immune Microenvironment (TIME) as Target for Therapy: A Focus on Innate Immunity Cells as Therapeutic Effectors. Int J Mol Sci. 2020; 21(9). PMC: 7247443. DOI: 10.3390/ijms21093125. View

Coffman L, Burgos-Ojeda D, Wu R, Cho K, Bai S, Buckanovich R . New models of hematogenous ovarian cancer metastasis demonstrate preferential spread to the ovary and a requirement for the ovary for abdominal dissemination. Transl Res. 2016; 175:92-102.e2. PMC: 5003680. DOI: 10.1016/j.trsl.2016.03.016. View

10.

Greco A, Mingrone G, Gasbarrini G . Free fatty acid analysis in ascitic fluid improves diagnosis in malignant abdominal tumors. Clin Chim Acta. 1995; 239(1):13-22. DOI: 10.1016/0009-8981(95)06093-s. View

11.

Yin M, Shen J, Yu S, Fei J, Zhu X, Zhao J . Tumor-Associated Macrophages (TAMs): A Critical Activator In Ovarian Cancer Metastasis. Onco Targets Ther. 2019; 12:8687-8699. PMC: 6814357. DOI: 10.2147/OTT.S216355. View

12.

Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Lopes C . Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas. Ann Oncol. 2004; 15(10):1535-42. DOI: 10.1093/annonc/mdh387. View

13.

Kenny H, Chiang C, White E, Schryver E, Habis M, Romero I . Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J Clin Invest. 2014; 124(10):4614-28. PMC: 4191043. DOI: 10.1172/JCI74778. View

14.

John B, Naczki C, Patel C, Ghoneum A, Qasem S, Salih Z . Regulation of the bi-directional cross-talk between ovarian cancer cells and adipocytes by SPARC. Oncogene. 2019; 38(22):4366-4383. PMC: 6542715. DOI: 10.1038/s41388-019-0728-3. View

15.

Tan D, Agarwal R, Kaye S . Mechanisms of transcoelomic metastasis in ovarian cancer. Lancet Oncol. 2006; 7(11):925-34. DOI: 10.1016/S1470-2045(06)70939-1. View

16.

Kumari A, Shonibare Z, Monavarian M, Arend R, Lee N, Inman G . TGFβ signaling networks in ovarian cancer progression and plasticity. Clin Exp Metastasis. 2021; 38(2):139-161. PMC: 7987693. DOI: 10.1007/s10585-021-10077-z. View

17.

Cai Q, Yan L, Xu Y . Anoikis resistance is a critical feature of highly aggressive ovarian cancer cells. Oncogene. 2014; 34(25):3315-24. PMC: 4333142. DOI: 10.1038/onc.2014.264. View

18.

Dutsch-Wicherek M, Szubert S, Dziobek K, Wisniewski M, Lukaszewska E, Wicherek L . Analysis of the treg cell population in the peripheral blood of ovarian cancer patients in relation to the long-term outcomes. Ginekol Pol. 2019; 90(4):179-184. DOI: 10.5603/GP.2019.0032. View

19.

Fujishita T, Kojima Y, Kajino-Sakamoto R, Mishiro-Sato E, Shimizu Y, Hosoda W . The cAMP/PKA/CREB and TGFβ/SMAD4 Pathways Regulate Stemness and Metastatic Potential in Colorectal Cancer Cells. Cancer Res. 2022; 82(22):4179-4190. DOI: 10.1158/0008-5472.CAN-22-1369. View

20.

Cai J, Gong L, Li G, Guo J, Yi X, Wang Z . Exosomes in ovarian cancer ascites promote epithelial-mesenchymal transition of ovarian cancer cells by delivery of miR-6780b-5p. Cell Death Dis. 2021; 12(2):210. PMC: 7904844. DOI: 10.1038/s41419-021-03490-5. View